

Letter to the editor in response to: Evidence in support of the international association of diabetes in pregnancy study groups' criteria for diagnosing gestational diabetes worldwide in 2019



TO THE EDITORS: We read with interest the data on the long-term risks of untreated mild hyperglycemia from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study.¹ Any national or international debate on the diagnostic criteria for gestational diabetes mellitus (GDM) also should be informed by the changes in preanalytical laboratory standards for measuring maternal plasma glucose since HAPO. For the HAPO study, glycolysis was inhibited by placing samples in a sodium fluoride additive on an ice water slurry and cell separation within 60 minutes.² Since 2011, it is recommended that cell separation takes place within 30 minutes and if this is not possible that sample tubes contain citrate buffer, not sodium fluoride.³ In 121 women selectively screened for GDM with a 1-step 75-g oral glucose tolerance test in our hospital, the stricter guidelines increased the rate of GDM from 14.2% (n = 22) under customary conditions to 38.1% (n = 59) applying the 2011 standards ($P < .01$).⁴ Failure to implement contemporary laboratory standards may lead to the diagnosis of GDM being missed and to underestimation of the prevalence.

Epidemiologically, if following inadequate inhibition of glycolysis, cases of more severe hyperglycemia continue to be classified as GDM but milder cases of hyperglycemia are erroneously included in the non-GDM group (see Table 1),¹ then the long-term risk of GDM may be statistically exaggerated. It also means that in obstetric practice women with mild GDM potentially undiagnosed may miss the window of opportunity for positive interventions highlighted.¹

As part of the diagnostic debate, we also suggest that long-term risks of GDM be calculated based on an adjusted odds ratio of 2.0 for delivery and neonatal outcomes favored by some professional bodies in North America, rather than 1.75 favored by others.¹ The frequency of primary outcomes were categorized by equal ranges of mg/dL into 7 plasma glucose categories for fasting plasma glucose, and continuous relationships were evident with no obvious cut-off point for risk (see Figure 1).¹ However, the numbers of women in each category is unstated. As the clinical outcomes were based on centiles, we also suggest categorizing the glucose measurements by population centiles, which might identify a cut-off centile that optimizes diagnostic sensitivity and specificity. Although we appreciate the expert call to immediate action on broadening consensus, we believe there may be merit in further contemplation of the data already collected by HAPO. ■

Eimer G. O'Malley, MRCPI
Ciara M. E. Reynolds, MSC
Michael J. Turner, FRCPI
UCD Centre for Human Reproduction
Coombe Women and Infants University Hospital
Dublin, Ireland
eimer.om@gmail.com

REFERENCES

1. Hod M, Kapur A, McIntyre HD. Evidence in support of the international association of diabetes in pregnancy study groups' criteria for diagnosing gestational diabetes worldwide in 2019. *Am J Obstet Gynecol* 2019 Jan; <https://doi.org/10.1016/j.ajog.2019.01.206>.
2. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. *Clin Chem* 2002;48: 436–72.
3. Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. *Clin Chem* 2011;57:e1–47.
4. Daly N, Flynn I, Carroll C, Farren M, McKeating A, Turner MJ. Impact of implementing preanalytical laboratory standards on the diagnosis of gestational diabetes mellitus: a prospective observational study. *Clin Chem* 2016;62:387–91.

© 2019 Elsevier Inc. All rights reserved. <https://doi.org/10.1016/j.ajog.2019.02.041>

REPLY



We thank O'Malley et al for their interest in our clinical opinion.¹ They correctly highlight the importance of sampling technique, specimen transport, and laboratory methodology in the diagnosis of gestational diabetes mellitus (GDM). Although their arguments relate primarily to pre-analytic variation, we note that, as clearly reported by Agarwal et al,² analytic variations also have a major potential impact, with the frequency of GDM diagnoses potentially halving or doubling depending on analytic variations within the acceptable (approximately 5%) range for well standardized glucose measurements.

However, we do not consider that these issues are relevant to interpretation of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) and HAPO follow-up studies as reported in Table 1 of our paper.¹ Pregnancy glucose